Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), a $15.77 billion market cap company with an "Excellent" financial health rating according to InvestingPro, executed a ...

United Therapeutics said the FDA has cleared it to begin the first clinical trial testing whether organs from gene-edited ...

United Therapeutics is pioneering a new frontier in organ transplants using pig kidneys. STORY HIGHLIGHTS FDA clears United Therapeutics for human trials of pig-to-human kidney transplants.

Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock transactions, according to a recent SEC filing. On February 3, Benkowitz sold shares ...

The U.S. Food and Drug Administration has approved the first-ever clinical trials testing pig kidney transplants in people ...

UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics ...

It's as significant for the medical community as it is for the local business. Silver Spring’s United Therapeutics Corp. (NASDAQ: UTHR) has scored a regulatory green light to start clinical ...

The second person ever has received a transplant with a genetically modified pig kidney.

United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...

Mass General Brigham has announced the successful completion of another gene-edited pig kidney transplant, the first of a ...

It is hard to get excited after looking at United Therapeutics' (NASDAQ:UTHR) recent performance, when its stock has declined 7.4% over the past three months. However, a closer look at its sound ...

It was the fourth pig kidney transplant in the United States, and the first of three that will be done at Mass General as ...